Study links depression to energy production dysfunction in brain and blood cells

For decades, the dominant explanation for major depressive disorder has centered on neurotransmitters, particularly serotonin and dopamine, and how their availability in the brain affects mood. That model has driven antidepressant development for 40 years, producing drugs that work for roughly half of patients who try them. A study published in Nature Mental Health in March 2025 offers a different angle: depression may also involve a measurable dysfunction in how cells produce energy at the mitochondrial level.

The research team, led by scientists at the University of Cambridge and King's College London, analyzed mitochondrial function in two cell types from 64 young adults with major depressive disorder and 35 healthy controls. They found that cells from participants with depression produced significantly more ATP, the molecule cells use for energy, at rest compared to controls. When those same cells were stressed and required to increase output, their ATP production capacity was lower than in the healthy group. The pattern held in both neurons derived from stem cells and in blood platelets, suggesting the dysfunction is systemic rather than limited to the brain.

What mitochondria do and why their dysfunction matters for mood

Mitochondria generate ATP through oxidative phosphorylation, a process that uses oxygen and glucose to produce energy for cellular functions. Brain cells are among the most metabolically demanding cells in the body, consuming roughly 20 percent of the body's total energy budget despite representing about 2 percent of body weight. Neurons need continuous, on-demand ATP to maintain membrane potential, release neurotransmitters, and support synaptic plasticity, the process by which connections between neurons strengthen or weaken with experience.

If a neuron's mitochondria are running at a high baseline output but cannot scale up under demand, the cell faces a problem similar to a power grid that is fully loaded at idle and has no spare capacity when demand spikes. Synaptic transmission, which requires bursts of ATP to release neurotransmitter vesicles, would be the first process affected. The Cambridge and King's team proposed that this reduced energy reserve capacity in neurons could contribute to the cognitive sluggishness, emotional blunting, and fatigue that characterize depression in many patients.

How the experiment was designed and what it measured

The study used a technique called Seahorse XF analysis to measure oxygen consumption rates in live cells, which provides a real-time readout of mitochondrial activity. Cells were first measured at baseline, then exposed to a series of chemical stressors that force mitochondria to work harder or shut down, allowing the researchers to calculate spare respiratory capacity, which is the difference between a cell's maximum possible ATP output and its resting output.

Participants with depression showed a 28 percent reduction in spare respiratory capacity in platelet cells compared to healthy controls. In neurons derived from induced pluripotent stem cells reprogrammed from participant skin cells, the reduction in spare capacity was 31 percent. Both results were statistically significant at p less than 0.001 after correction for multiple comparisons. The study also measured basal respiration, the resting rate of mitochondrial activity, and found it was 19 percent higher in the depression group, consistent with a system running hot at baseline but lacking reserve capacity.

Why blood platelets show the same pattern as neurons

Platelets are small blood cells primarily known for their role in clotting, but they contain functional mitochondria and have been used as a proxy for neuronal mitochondrial function in research for over two decades. Platelets and neurons share common mitochondrial regulatory pathways, and several studies have found that platelet mitochondrial dysfunction correlates with brain mitochondrial dysfunction in conditions including Alzheimer's disease and Parkinson's disease. The fact that the Cambridge team observed the same pattern in both cell types strengthens the argument that the dysfunction is not specific to the central nervous system.

Using platelets as a diagnostic proxy is also practically significant. Getting a blood sample is far simpler than deriving neurons from stem cells, which requires a multi-week laboratory protocol and specialized facilities. If the platelet mitochondrial signature holds up in larger studies, it could eventually be developed into a blood-based biomarker for depression, which would be the first objective laboratory test for the condition. Current depression diagnosis relies entirely on clinical interview and self-reported symptoms.

How this intersects with existing antidepressant mechanisms

The finding does not invalidate the neurotransmitter model of depression. It complicates it. Mitochondrial dysfunction and neurotransmitter dysregulation are not mutually exclusive; they can occur together and may reinforce each other. Serotonin synthesis in neurons requires ATP, and glutamate receptor activity, which is targeted by ketamine-based antidepressants, directly regulates mitochondrial calcium handling. The Cambridge team suggested in their paper that the mitochondrial dysfunction they observed could be upstream of some neurotransmitter abnormalities rather than a separate, parallel cause.

This matters for drug development. If mitochondrial spare capacity can be restored or preserved with pharmacological interventions, it could improve treatment outcomes in patients who do not respond to existing antidepressants. Several compounds already in development for mitochondrial diseases, including MitoQ and SS-31 peptides, have shown promise in preclinical models of neurological conditions. Neither has been tested in depression specifically, but the Cambridge findings give researchers a plausible rationale to pursue that work.

Limitations of the study and what comes next

The study enrolled 64 participants with depression and 35 controls, which is a moderate sample size for this type of mechanistic research but too small to draw population-level conclusions. All participants were young adults between 18 and 25, and the results may not generalize to older populations, where mitochondrial function declines for age-related reasons independent of depression. The study also could not establish whether the mitochondrial dysfunction causes depression, results from it, or is a downstream effect of the chronic stress and sleep disruption that accompany the condition.

The team has already begun a follow-up study with 200 participants that will include longitudinal measurements, tracking mitochondrial function before and after antidepressant treatment to determine whether the dysfunction resolves when depression remits or persists as a trait marker. That study is expected to report initial results in late 2026. If mitochondrial spare capacity normalizes with successful antidepressant treatment, it would suggest the dysfunction is a state marker driven by the illness. If it persists after remission, it would indicate a stable biological trait that may predict relapse risk.